My research focuses on developing and evaluating methods to assess comparative effectiveness and safety
for health care interventions. The great importance of these topics has
received increasing recognition in recent years among government
funding and regulatory agencies, as well as in the medical community at large.
For example, the US Patient Protection and Affordable Care Act of 2010
established the Patient-Centered Outcomes
Research Institute to conduct research regarding the benefits and harms of
health care treatments for different segments of the population. This
new institute's work is to build on the results of $1.1 billion of
funding allocated to comparative effectiveness
research through the American Recovery and Reinvestment Act of 2009.
Additionally, the Prescription Drug User Fee Act (PDUFA) directed the
US FDA to significantly increase
focus on and funding for post-market safety assessment of drugs and
medical devices starting in 2008.
My work concentrates around two key aspects of
safety and effectiveness research.
My primary area of expertise is research synthesis, or
meta-analysis. Research synthesis not only reduces
the cost of important discoveries, but is the only practical way to
empirically evaluate interventions for diverse and fragile populations.
My program in research synthesis has three
components: evaluation of randomized trial generalizability, synthesis of data collected
with randomized and observational designs, and assessment of treatment
on rare event outcomes.
More recently, I have also been working on the use of genetic biomarkers
to improve treatment effectiveness and safety. Through genetic
association analyses, modern healthcare can realize the promise of personalized
medicine to accurately choose interventions most effective and safe
for each individual.
You can learn about my professional history by reading my curriculum vitae
(updated 11/12) and my teaching